Clinical Trial Update: TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TransCon TLR7/8 agonist, TransCon IL-2 beta/gamma, and pembrolizumab before surgery in advanced head and neck squamous cell carcinoma w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TransCon IL-2 β/γ
• TransCon TLR7/8 Agonist

Snippet

Sponsor: Ascendis Pharma A/S | Conditions: Head and Neck Neoplasms | Phase 2 | Status: TERMINATED